Tenax Therapeutics Stock Today
| TENX Stock | USD 3.50 0.06 1.69% |
Performance0 of 100
| Odds Of DistressOver 85
|
Tenax Therapeutics is trading at 3.50 as of the 24th of April 2024; that is -1.69 percent down since the beginning of the trading day. The stock's open price was 3.56. Tenax Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Tenax Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of March 2024 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of January 1997 | Category Healthcare | Classification Health Care |
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina. The company has 1.96 M outstanding shares of which 48.99 K shares are at this time shorted by private and institutional investors with about 0.32 trading days to cover. More on Tenax Therapeutics
Moving against Tenax Stock
| 0.86 | CNTA | Centessa Pharmaceuticals Downward Rally | PairCorr |
| 0.84 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
| 0.83 | PAHC | Phibro Animal Health Financial Report 1st of May 2024 | PairCorr |
| 0.78 | MRUS | Merus BV Financial Report 2nd of May 2024 | PairCorr |
| 0.72 | OPT | Opthea | PairCorr |
| 0.72 | ANIP | ANI Pharmaceuticals Financial Report 13th of May 2024 | PairCorr |
| 0.64 | KROS | Keros TherapeuticsInc Financial Report 2nd of May 2024 | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Financial Report 20th of May 2024
Tenax Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Tenax Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Tenax Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO | Christopher Giordano | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Tenax Therapeutics report their recommendations after researching Tenax Therapeutics' financial statements, talking to executives and customers, or listening in on Tenax Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Tenax Therapeutics. The Tenax consensus assessment is calculated by taking the average forecast from all of the analysts covering Tenax Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Tenax Therapeutics' liquidity, profitability, solvency, and operating efficiency, Tenax Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Tenax Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tenax Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Tenax Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tenax Therapeutics' financial leverage. It provides some insight into what part of Tenax Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tenax Therapeutics (TENX) is traded on NASDAQ Exchange in USA. It is located in 101 Glen Lennox Drive, Chapel Hill, NC, United States, 27517 and employs 5 people. Tenax Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.97 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Tenax Therapeutics's market, we take the total number of its shares issued and multiply it by Tenax Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Tenax Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.96 M outstanding shares of which 48.99 K shares are at this time shorted by private and institutional investors with about 0.32 trading days to cover.
Tenax Therapeutics currently holds about 7.23 M in cash with (5.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29.
Check Tenax Therapeutics Probability Of Bankruptcy
Ownership AllocationAbout 96.0 % of Tenax Therapeutics outstanding shares are held by general public with 0.355 (%) owned by insiders and only 4.07 % by institutional holders.
Check Tenax Ownership Details
Tenax Stock Price Odds Analysis
Based on a normal probability distribution, the odds of Tenax Therapeutics jumping above the current price in 90 days from now is about 76.02%. The Tenax Therapeutics probability density function shows the probability of Tenax Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.1372. This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Tenax Therapeutics will likely underperform. Additionally, tenax Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Tenax Therapeutics to move above the current price in 90 days from now is about 76.02 (This Tenax Therapeutics probability density function shows the probability of Tenax Stock to fall within a particular range of prices over 90 days) .
Tenax Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Tenax Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Tenax Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Tenax Therapeutics' value.| Instituion | Recorded On | Shares | |
| Millennium Management Llc | 2023-09-30 | 0.0 | |
| Lido Advisors, Llc | 2023-12-31 | 0.0 | |
| Lpl Financial Corp | 2023-12-31 | 0.0 | |
| Honkamp Krueger Financial Services Inc | 2023-12-31 | 0.0 | |
| Virtu Financial Llc | 2023-12-31 | 0.0 | |
| Two Sigma Securities, Llc | 2023-12-31 | 0.0 | |
| Hrt Financial Llc | 2023-09-30 | 0.0 | |
| Ci Private Wealth Llc | 2023-09-30 | 191.5 K | |
| Geode Capital Management, Llc | 2023-09-30 | 119 K | |
| State Street Corporation | 2023-09-30 | 95.1 K | |
| Blackrock Inc | 2023-09-30 | 23.9 K |
Tenax Therapeutics Historical Income Statement
Tenax Therapeutics Income Statement is one of the three primary financial statements used for reporting Tenax's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Tenax Therapeutics revenue and expense. Tenax Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Tenax Therapeutics' Other Operating Expenses is fairly stable compared to the past year. Research Development is likely to rise to about 3.6 M in 2024, whereas Depreciation And Amortization is likely to drop 7,192 in 2024. View More FundamentalsTenax Stock Against Markets
Picking the right benchmark for Tenax Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Tenax Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Tenax Therapeutics is critical whether you are bullish or bearish towards Tenax Therapeutics at a given time. Please also check how Tenax Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Tenax Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Tenax Therapeutics Corporate Directors
Tenax Therapeutics corporate directors refer to members of a Tenax Therapeutics board of directors. The board of directors generally takes responsibility for the Tenax Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Tenax Therapeutics' board members must vote for the resolution. The Tenax Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Anthony DiTonno | Independent Director | Profile | |
| Gerald Proehl | Director | Profile | |
| Gregory Pepin | Independent Director | Profile | |
| Chris Rallis | Independent Director | Profile |
How to buy Tenax Stock?
Before investing in Tenax Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Tenax Therapeutics. To buy Tenax Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Tenax Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Tenax Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Tenax Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Tenax Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Tenax Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.
Already Invested in Tenax Therapeutics?
The danger of trading Tenax Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Tenax Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Tenax Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Tenax Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Tenax Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tenax Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tenax Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tenax Therapeutics Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Tenax Stock analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
Is Tenax Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tenax Therapeutics. If investors know Tenax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tenax Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (31.04) | Return On Assets (0.68) | Return On Equity (1.61) |
The market value of Tenax Therapeutics is measured differently than its book value, which is the value of Tenax that is recorded on the company's balance sheet. Investors also form their own opinion of Tenax Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tenax Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tenax Therapeutics' market value can be influenced by many factors that don't directly affect Tenax Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tenax Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tenax Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tenax Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.